Built on evidence.

Agrarius™ has been evaluated through universities, agricultural institutions, independent researchers, growers and commercial partners.

Reported outcomes have varied by crop, geography and study conditions, as would be expected in agricultural research. Collectively, however, these programs have produced a growing body of evidence supporting the ability of Agrarius™ to influence measurable indicators of plant performance.

Agrarius™ has also progressed into commercial sales, providing a foundation for broader market development and adoption.

Quicksome™ has been incorporated into revenue-generating consumer health and nutraceutical products.

These applications provide commercial evidence that the technology can be formulated, manufactured and incorporated into finished products while the Company advances the platform into additional formulation opportunities.

Quicksome™ and related formulation programs have been evaluated through third-party preclinical studies, CRO work and internal formulation development.

This work has contributed to the Company's understanding of formulation, delivery, stability and the molecule-specific requirements that can influence potential performance.

Peptides represent an important area of formulation development for Quicksome™.

Many peptide molecules face significant stability and delivery challenges, particularly when administered through conventional oral formats.

The Company has completed initial Quicksome™ sublingual formulation work involving multiple peptide molecules, including BPC-157, GHK-Cu, KPV, SNAP-8 and retatrutide. Current programs are focused on evaluating sublingual delivery applicability, formulation characteristics and potential commercial pathways within the compounded pharmacy market.

This work remains molecule-specific and developmental. The Company does not own the underlying peptide molecules, and any future commercialization will depend upon applicable regulatory requirements and legally authorized commercial pathways.

Quicksome™ development has included a fenugreek glycosides formulation evaluated for its effect on testosterone levels, together with product development addressing hot flash and night sweat symptoms associated with perimenopause and post-menopause.

The Company continues to explore additional applications where sublingual formulation may create advantages in hormonal health and personalized medicine.

Many biological molecules depend upon injection because conventional oral administration cannot provide a viable delivery pathway.

The Company has explored the potential application of Quicksome™ to the sublingual delivery of rapid-acting human insulin and other molecules historically administered by injection.

This work remains exploratory and has not established Quicksome™ as an alternative to any approved injectable product.

It does, however, demonstrate the larger question the platform was designed to explore:

Can advanced formulation and sublingual delivery create more practical ways to administer important molecules?

An evaluation performed by the United States Food and Drug Administration Polio Vaccine Laboratory confirmed the preservation of Polio D-antigen in the Company's proprietary Quicksome™ rapid-dissolve sublingual technology.

The FDA laboratory provided ELISA testing services to evaluate the Company's ability to preserve the Polio D-antigen within the Quicksome™ formulation.

The Company subsequently entered into a formal two-year collaborative research agreement with the FDA supporting continued research, development and evaluation of its Quicksome™ controlled cold chain technology.

This body of work extends beyond a single vaccine formulation.

It provides important evidence supporting further investigation of Quicksome™ with temperature-sensitive biological materials, including vaccines, peptides, proteins and other molecules affected by storage and transportation limitations.

The research did not constitute FDA approval or endorsement of Quicksome™ or any Quicksome™-enabled product.

Soluvec™ demonstrates more than the performance of one ivermectin formulation.

It provides peer-reviewed evidence that the Quicksol™ process can materially alter the formulation and pharmacokinetic characteristics of a molecule historically constrained by poor aqueous solubility.

This creates a scientific foundation for investigating how solubilization may enable different formulations, routes of administration, exposure profiles and potential applications.

The Company's intellectual property portfolio includes a granted patent covering injectable, infusable and instillable solubilized ivermectin applications as an adjuvant for cancer therapies.

The Company also explored potential combinations involving solubilized ivermectin with existing chemotherapeutic and immunomodulatory approaches.

This work remains preclinical and does not establish Soluvec™ as a safe or effective cancer therapy.

Its significance lies in demonstrating the broader therapeutic research opportunities that can emerge when the formulation and potential administration pathways of an existing molecule are changed.

The Company completed third-party preclinical research involving its solubilized ivermectin technology in a Biosafety Level 4 laboratory environment.

The Company reported that in vitro testing demonstrated the same antiviral effect at the tested concentration after 24 hours and again after 48 hours across all three variants.

The research also included a transgenic mouse model evaluating viral replication and clearance following administration of the solubilized formulation.

This work was exploratory and preclinical. It did not establish the formulation as an approved treatment for COVID-19 or any other viral disease.

It does, however, provide another example of the potential research pathways created by changing the solubility and delivery characteristics of a poorly water-soluble molecule.